Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Identification of Genetic Variants Influencing the Likelihood of Methotrexate-Induced Mucositis Development in Children Using Pathway Analysis

FY 2022-23

Summary
Methotrexate, while an effective, widely used drug in childhood cancer, causes debilitating mucositis — a painful condition in various soft tissues, which often results in the inability to eat and subsequently, malnutrition. In severe cases, open sores lead to life-threatening infections. Supportive care often requires frequent hospitalization, adding to the burden and reducing quality of life for the patients and their caregivers. Since genetic differences influence the susceptibility and severity of mucositis, uncovering genetic contributions can help understand the pathobiology underlying methotrexate-induced mucositis. Our study aims to pinpoint the hidden genetic components that cause some children to have more severe mucositis while others tolerate the treatment better. We are examining how differences within genes that work together contribute to mucositis by analyzing genomic data generated for 497 methotrexate-treated pediatric cancer patients recruited across 6 Canadian sites by the Canadian Pharmacogenomics Network for Drug Safety (CPNDS). This will be followed by validation in an additional patient population of 142 methotrexate-treated children recruited through the CPNDS. Ultimately, our research can empower the health care team to identify and prioritize care for pediatric patients at high risk for this debilitating methotrexate-induced adverse reaction. Moreover, knowledge gained from this research project will help identify future treatment targets for mucositis arising from cancer therapy.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
485887
Name
Zhang XIAO YU
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identification of Genetic Variants Influencing the Likelihood of Methotrexate-Induced Mucositis Development in Children Using Pathway Analysis
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adverse Drug Reactions Surveillance; Bioinformatics And Biotechnology; Gene Set Enrichment Analysis; Medical Genetics; Methotrexate; Mucositis; Oncology Clinical Practice; Pathobiological Pathways; Pediatrics; Pharmacogenomics
Abstract
Methotrexate, while an effective, widely used drug in childhood cancer, causes debilitating mucositis — a painful condition in various soft tissues, which often results in the inability to eat and subsequently, malnutrition. In severe cases, open sores lead to life-threatening infections. Supportive care often requires frequent hospitalization, adding to the burden and reducing quality of life for the patients and their caregivers. Since genetic differences influence the susceptibility and severity of mucositis, uncovering genetic contributions can help understand the pathobiology underlying methotrexate-induced mucositis. Our study aims to pinpoint the hidden genetic components that cause some children to have more severe mucositis while others tolerate the treatment better. We are examining how differences within genes that work together contribute to mucositis by analyzing genomic data generated for 497 methotrexate-treated pediatric cancer patients recruited across 6 Canadian sites by the Canadian Pharmacogenomics Network for Drug Safety (CPNDS). This will be followed by validation in an additional patient population of 142 methotrexate-treated children recruited through the CPNDS. Ultimately, our research can empower the health care team to identify and prioritize care for pediatric patients at high risk for this debilitating methotrexate-induced adverse reaction. Moreover, knowledge gained from this research project will help identify future treatment targets for mucositis arising from cancer therapy.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Zhang, XIAO YU
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~